

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 September 2022 (09.09.2022)



(10) International Publication Number
WO 2022/187142 A1

(51) International Patent Classification:

A61K 31/195 (2006.01) A61K 31/785 (2006.01)
A61K 31/4418 (2006.01) A61P 13/12 (2006.01)

(21) International Application Number:

PCT/US2022/018152

(22) International Filing Date:

28 February 2022 (28.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/155,022 01 March 2021 (01.03.2021) US

(71) Applicant: **AKEBIA THERAPEUTICS, INC.** [US/US];
245 First Street, Suite 1400, Cambridge, Massachusetts
02142 (US).

(72) Inventors: **CHAVAN, Ajit**; c/o Akebia Therapeutics, Inc.,
245 First Street, Suite 1400, Cambridge, Massachusetts
02142 (US). **BURKE, Steven**; c/o Akebia Therapeutics,

Inc., 245 First Street, Suite 1400, Cambridge, Massachusetts
02142 (US).

(74) Agent: **ESPINO, Christine G.**; Proskauer Rose LLP, One
International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: MODULATION OF DRUG-DRUG INTERACTIONS OF VADADUSTAT




FIG. 1

(57) Abstract: Provided herein are methods for reducing, minimizing, or controlling drug-drug interactions resulting from administration of a drug (e.g., a first drug) that is vadadustat (i.e., {5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl}amino}acetic acid (Compound 1)) and another (e.g., a second) drug (e.g., a drug comprising a polymeric amine that binds phosphate (e.g., sevelamer hydrochloride or sevelamer carbonate); or inhibitors and/or substrates of certain proteins, receptors, and/or transporters (e.g., probenecid, cyclosporine, rifampin, digoxin, or adefovir))

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*